Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme

By sjmartinez • June 13, 2023

Fleischmann R, Curtis JR, Charles-Schoeman C, Mysler E, Yamaoka K, Richez C, Palac H, Dilley D, Liu J, Strengholt S, Burmester G. Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme. Ann Rheum Dis. 2023 Jun 12:ard-2023-223916. doi: 10.1136/ard-2023-223916. Epub ahead of print. PMID: 37308218.

Tags: Antirheumatic Agents, Arthritis, cardiovascular diseases, methotrexate, Publications, Rheumatology, tumor necrosis factor inhibitors

DASC-LOT Framework and S3 Metric: A Novel Evaluation and Benchmarking Method to Assess Initiation, Duration, and Spectrum of Antimicrobial Usage at Inpatient Hospital Settings

Goto M, Imai S, Cho H, Merchant JA, Goetz MB, Perencevich EN, Alexander B, Shi Q, Holcombe A, Livorsi DJ. DASC-LOT Framework and S3 Metric:[...]

A Hierarchical and Multiscale Framework for Characterizing Mouse Sleep-Wake Dynamics from 14-Day Continuous EEG: Validation of Age- and Sex-Dependent Remodeling

Kostin A, Saevskiy A, Alam MA, Jiang Y, Suntsova N, Alam MN. A Hierarchical and Multiscale Framework for Characterizing Mouse Sleep-Wake Dynamics from 14-Day Continuous[...]

Intent to Accept a Valley Fever Vaccine for Humans and Dogs and Factors Influencing Intended Uptake: A Cross-Sectional Survey in Two Endemic Regions

Hermann JN, Kruger SE, Wodniak N, Holland J, Janosick V, Sanchez A, Zuniga-Moya JC, Brucker D, Torres B, Melo KM, Oliveros E, Kuran R, D'Assumpcao[...]